scholarly journals Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life

1993 ◽  
Vol 67 (2) ◽  
pp. 402-406 ◽  
Author(s):  
SCA Fraser ◽  
HJ Dobbs ◽  
SR Ebbs ◽  
LJ Fallowfield ◽  
T Bates ◽  
...  
2003 ◽  
Vol 11 (3) ◽  
pp. 149-149
Author(s):  
Svetislav Vrbic ◽  
Ivica Pejcic ◽  
Sladjana Filipovic ◽  
Stojan Radic

Chemotherapy of breast cancer is still the area of intensive research. Based on mathematical model of tumor cell growth kinetics, articulated by Larry Norton, novel concept of chemotherapy in breast cancer was launched and it implies dose-densification of chemotherapy trough the use of sequential non cross-resistant single agents or regimens. The introduction of primary systemic chemotherapy (PST) improved the outcome of patients with locally advanced breast cancer (LABC). Simultaneous PST is the standard approach to patients with LABC nowadays. On the other hand, many studies using two most active cytotoxic drugs in primary breast cancer, anthracyclines and taxanes showed that sequential dose-dense single agent PST could be superior in terms of enhancing the rates of patients suitable for conservative surgery. In the light of this data, based on the results of the new clinical trials we will discuss merits and demerits of using sequential dose-dense single agent chemotherapy in LABC.


2004 ◽  
Vol 31 (5) ◽  
pp. 977-983 ◽  
Author(s):  
Judith A. Headley ◽  
Kristin K. Ownby ◽  
Lauri D. John

2004 ◽  
Vol 19 (2) ◽  
pp. 139-155 ◽  
Author(s):  
Trace Kershaw ◽  
Laurel Northouse ◽  
Charuwan Kritpracha ◽  
Ann Schafenacker ◽  
Darlene Mood

2019 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Kendra Kamp ◽  
Megan Flanigan ◽  
Kanjana Thana ◽  
Jodi Terpstra ◽  
Gwen Wyatt ◽  
...  

The Breast ◽  
2019 ◽  
Vol 44 ◽  
pp. 108-112 ◽  
Author(s):  
Caterina Calderon ◽  
Alberto Carmona-Bayonas ◽  
Raquel Hernández ◽  
Ismael Ghanem ◽  
Beatriz Castelo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document